Compare Illumina, Inc. (ILMN) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Snap Inc — how do they compare? Illumina, Inc. trades at $189.71 (market cap $27.94B), while Snap Inc trades at $4.59 (market cap $7.67B). The key difference: Illumina, Inc. is far larger — about 3.6× Snap Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | SNAP | |
|---|---|---|
Market Cap | $27.94B | $7.67B |
Sector | Health | Media |
52-Week High | $194.33 | $10.35 |
52-Week Low | $91.00 | $3.93 |
Enterprise Value | $29.33B | $9.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Snap Inc. (SNAP) trades at $4.585, up 1.33% on the day, amid a bearish technical signal and mixed fundamentals. Revenue grew to $5.93 billion in 2025, but the company posted a net loss of $460.49 million, with a negative net margin of -6.72%. Recent news highlights the launch of high-priced AR glasses, which sparked investor concerns and a stock decline. The stock faces resistance near $5, with analyst consensus price target at $5.75, suggesting modest upside potential from current levels.
The outlook remains cautious; while cost-cutting and AR innovation offer long-term growth avenues, persistent losses, competitive pressures, and high debt levels pose significant risks. Investor sentiment is divided, with analysts mostly neutral to bullish, but the stock's performance hinges on achieving profitability and successful monetization of new initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
